News | March 15, 2023
LifeSigns raises Pre-Series A
A funding to expand operations and provide better patient care
A funding to expand operations and provide better patient care
Lupin Bioresearch Centre conducts BA/BE, PK/PD, In-vitro BE and biosimilar studies.
Proposed combination enhances Pfizer’s position as a leading company in oncology
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
The company will be submitting the responses to US FDA observations within stipulated timeline
Open, scalable, end-to-end solution to improve diagnostic quality and efficiency
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
The inspection concluded with no observations
Time to combine innovation, access and technology to deliver positive patient outcomes
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Subscribe To Our Newsletter & Stay Updated
